NEW YORK (Reuters Health)—Patients treated with biologic therapy for rheumatoid arthritis, inflammatory bowel disease and psoriasis don’t appear to be at increased risk of melanoma, according to the results of a systematic review and meta-analysis.
Conferences
Adjuvant pembrolizumab confers durable RFS benefit in resected stage III melanoma
Adjuvant pembrolizumab taken for up to 1 year conferred a durable, clinically meaningful RFS benefit for patients with resected high-risk stage III melanoma, according to study results presented during the ASCO20 Virtual Scientific Program.
Survival Benefit Continues With Encorafenib Plus Binimetinib in BRAF V600E+ Melanoma
Encorafenib (Braftovi) plus binimetinib (Mektovi) show sustained overall survival (OS) and progression-free survival (PFS) benefit in patients with BRAF V600–mutant melanoma, according to updated findings from the COLUMBUS (NCT01909453) study, presented in a poster at the 2020 American Society of Clinical Oncology Virtual Scientific Program.
Encorafenib/Binimetinib Combo Continues to Show Survival Benefits in BRAF V600-Mutant Melanoma
The combination of encorafenib (Braftovi) and binimetinib (Mektovi) demonstrated continuing benefit in overall survival (OS) and progression-free survival (PFS) for patients with BRAF V600—mutant melanoma, according to an updated analysis of the COLUMBUS (NCT01909453) trial during a poster presentation at the 2020 American Society of Clinical Oncology Virtual Scientific Program.